Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Sichuan University

Headquarters: Chengdu, China
Year Founded: 1910
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting HIF2A for asthma

BioCentury | Apr 30, 2024
Distillery Therapeutics

Inhibiting ACSS2 for fibrotic kidney disease

BioCentury | Oct 27, 2023
Politics, Policy & Law

Oct. 27 Quick Takes: AbbVie pegs IRA cost at $2.1 billion

Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more
BioCentury | Jan 31, 2023
Distillery Therapeutics

RIPK1 inhibitor generated via deep learning

BioCentury | Dec 23, 2022
Discovery & Translation

Enhancer elements for tissue regeneration; plus Alentis’ mAb for fibrosis and more

BioCentury’s roundup of translational news
BioCentury | Dec 7, 2022
Distillery Therapeutics

DNA-scavenging nanoparticles for periodontitis

BioCentury | Sep 23, 2022
Discovery & Translation

Neonatal disease interception for Huntington disease; two self-assembling vaccines and more

BioCentury’s roundup of translational news
BioCentury | May 28, 2022
Discovery & Translation

A synthetic lethal pair; plus Arbor and more

BioCentury’s roundup of translational news
BioCentury | Dec 3, 2021
Distillery Therapeutics

FBXL2-mediated EGFR degradation for TKI-resistant NSCLC

BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

BioCentury’s roundup of translational news
Items per page:
1 - 10 of 24